Therefore, tyrosine kinase inhibitors (TKIs), such as imatinib as the first drug against the BCR-ABL TK, have been used in the therapy of most cases of CML patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.